Results 141 to 150 of about 175,178 (288)

CD19 [PDF]

, 2019
H. Renz, B. Gierten
openaire   +1 more source

Sjögren Disease—B Cells at the Brink: From Autoimmunity to Lymphomagenesis and the Rise of Novel B Cell–Targeted Therapies

Arthritis &Rheumatology, EarlyView.
Sjögren disease (SjD) is a common systemic autoimmune disorder characterized by inflammation of the exocrine glands, resulting in dryness. Patients frequently exhibit extraglandular manifestations affecting various organ systems. To date, there are no US Food and Drug Administration (FDA)‐approved disease‐modifying therapies for SjD. In this review, we
Rachael A. Gordon, Sara S. McCoy
wiley   +1 more source

Identification of Histone Deacetylase Inhibitor Targeting Type I Interferon and B Cell Abnormalities in Systemic Lupus Erythematosus

Arthritis &Rheumatology, EarlyView.
Objective Systemic lupus erythematosus (SLE) is characterized by increased Type I interferon (IFN‐I) and autoantibody production. This study aimed to identify drugs that can inhibit both IFN‐I and autoantibody production. Methods We identified an inhibitor of IFN‐I production from a chemical library.
Takehiro Hirayama, Hachiro Konaka, Yasuhiro Kato, Takayuki Shibahara, Chisato Nishizawa, Kohei Tsujimoto, JeongHoon Park, Eri Itotagawa, Tatsunori Jo, Masayuki Nishide, Sumiyuki Nishida, Yoshihito Shima, Masashi Narazaki, Wataru Aoki, Ken J Ishii, Hyota Takamatsu, Atsushi Kumanogoh   +16 more
wiley   +1 more source

Single‐Cell RNA Sequencing Informs Precision Targeting of Monogenic Lupus Associated With IKZF1 Haploinsufficiency

Arthritis &Rheumatology, EarlyView.
Objective This study aimed to investigate the mechanisms of immune dysregulation in a pediatric patient with monogenic lupus driven by IKZF1 haploinsufficiency. Methods Peripheral immune cells from a patient with IKZF1 haploinsufficiency, patients with lupus with no currently known genetic mutations, and healthy controls were analyzed using single‐cell
Qi Zheng, Yejun Tan, Zhaoling Wang, Yanjie Qian, Qian Ma, Danping Shen, Meiping Lu   +6 more
wiley   +1 more source

Risk Factors for Relapse in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis Among Patients With Relapse After Induction of Remission With Rituximab

Arthritis &Rheumatology, EarlyView.
Objective The objective of the study was to determine risk factors for relapse of antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV) after reinduction of remission with rituximab and discontinuation of maintenance therapy. Methods This is a post hoc analysis of the RITAZAREM clinical trial.
Ellen Romich, Joshua F. Baker, Thomas R. Riley IV, Ian Green, Rennie L. Rhee, Carol A. McAlear, Ulrich Specks, Rona M. Smith, David R. Jayne, Peter A. Merkel, for the RITAZAREM Investigators, Reem Al‐jayyousi, Yoshihiro Arimura, Jacqueline Andrews, Simon Bond, Marianna Nodale, Annette Bruchfeld, Brian Camilleri, Simon Carette, Chee Kay Cheung, Michael Clarkson, Janak de Zoysa, Vimal Derebail, Tim Doulton, Tomomi Endo, Eri Muso, Tatsuo Tsukamoto, Alastair Ferraro, Lindsy Forbess, Shouichi Fujimoto, Shunsuke Furuta, Ora Gewurz‐Singer, Yoshitomo Hamano, Lorraine Harper, Toshiko Ito‐Ihara, Rachel B. Jones, Nader Khalidi, Rainer Klocke, Curry L. Koening, Yoshinori Komagata, Hajime Kono, Shunya Uchida, Carol A. Langford, Peter Lanyon, Sarah Lawman, Raashid Luqmani, Larry W. Moreland, Kim Mynard, Patrick Nachman, Christian Pagnoux, Chen Au Peh, Charles Pusey, Dwarakanathan Ranganathan, Ken‐ei Sada, Richard Smith, Richard Watts, Robert Spiera, Antoine G. Sreih, Kazuo Suzuki, Vladamir Tesar, Augusto Vaglio, Giles Walters, Caroline Wroe   +62 more
wiley   +1 more source

Impact of measurable residual disease in combination with CD19 on postremission therapy choices for adult t(8;21) acute myeloid leukemia in first complete remission

Cancer Medicine
Background The post‐remission therapy (PRT) choices for adult t(8;21) acute myeloid leukemia (AML) in first complete remission (CR1) need to be further explored.
Xi Jia, Naying Liao, Sijian Yu, Huan Li, Hui Liu, Haiyan Zhang, Jun Xu, Yunqian Yao, Han He, Guopan Yu, Qifa Liu, Yu Zhang, Pengcheng Shi   +12 more
doaj   +1 more source

Single‐cell level characterization of B cell depletion and repopulation following rituximab in systemic lupus erythematosus

Arthritis &Rheumatology, Accepted Article.
Objective Rituximab, a CD20+ B cell depletion therapy, is frequently used to treat systemic lupus erythematosus (SLE). However, variability in patient response highlights the need for a deeper understanding of the underlying immune cell dynamics of B cell depletion and repopulation.
Haerin Jang, Norzawani Buang, Catherine Sutherland, Wanseon Lee, Lauren Overend, Tarran S. Rupall, Katie L. Burnham, Matthew C. Pickering, Marina Botto, Emma E. Davenport   +9 more
wiley   +1 more source

Interleukin‐2 deprived state of regulatory T cells and their recovery by low‐dose interleukin‐2 in patients with inflammatory myopathies

Arthritis &Rheumatology, Accepted Article.
Objective Regeneration and expansion of regulatory T cells (Treg) by low‐dose interleukin‐2 (IL‐2) therapy is considered a potential treatment strategy for a wide range of autoimmune diseases. To provide a pathophysiologically‐based rationale for low‐dose IL‐2 therapy, we investigated whether reversible defects in the Treg‐IL‐2 axis emerge in ...
Justus Ohmes, Luisa R. Monne, Sara Comdühr, Fynn Gerlach, Hanna Grasshoff, Alexander Dübbers, Antje Müller, Alexander Scheffold, Gabriela Riemekasten, Reza Akbarzadeh, Jens Y. Humrich   +10 more
wiley   +1 more source

Effect of developmental changes on pharmacokinetics of drugs used in the treatment of infant acute lymphoblastic leukaemia—A comprehensive review

British Journal of Clinical Pharmacology, EarlyView.
While the event‐free survival (EFS) of children treated for acute lymphoblastic leukaemia (ALL) has improved greatly in the last decades, the EFS for patients diagnosed with ALL before the age of one is still under 50%. This outcome further decreases when infants have a rearrangement in the gene encoding histone‐lysine N‐methyltransferase 2A (KMT2A ...
Tirsa de Kluis, Leiah J. Brigitha, Lidwien M. Hanff, Alwin D. R. Huitema, Inge M. van der Sluis, Meta H. M. Diekstra   +5 more
wiley   +1 more source

Pharmacokinetic modelling of intravenous immunoglobulin in children with primary immunodeficiencies and secondary antibody deficiencies

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims Children with primary immunodeficiency (PID) and secondary antibody deficiency (SAD) often require immunoglobulin replacement therapy due to low plasma immunoglobulin G (IgG) levels and recurrent infections. Existing pharmacokinetic models for immunoglobulin in PID patients predominantly focus on adults, with limited attention to ...
Iek Leng Cheng, Zhong Hui Huang, Austen Worth, Claire Booth, Joseph F. Standing   +4 more
wiley   +1 more source